How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

OSK Gene Therapy for Anti-Aging: Epigenetic Reprogramming and ER-100 Clinical Progress

Reversing Cellular Age: The First FDA-Cleared Gene Therapy for Antiaging

Recent advances in aging biology have culminated in a historic regulatory milestone. Life Biosciences, Inc. has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for ER-100, permitting the first human clinical evaluation of an epigenetic cellular rejuvenation therapy ⁽¹⁾. This decision represents a pivotal moment not only for the company, but for the broader field of regenerative and longevity medicine, as it signals the clinical translation of partial epigenetic reprogramming, a concept once confined to experimental biology. The Phase 1 study will primarily assess the safety, tolerability, and immunological effects of ER-100, while also exploring potential functional benefits in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.

ER-100 originates from Life Biosciences’ Partial Epigenetic Reprogramming platform, an approach designed to restore youthful cellular function through transient, controlled expression of three Yamanaka transcription factors, OCT4, SOX2, and KLF4 ⁽²⁾. Unlike genetic modification or gene editing technologies, this strategy does not alter the underlying DNA sequence. Instead, it seeks to reset epigenetic regulatory states that become disrupted during aging or disease, thereby enabling cells to recover more youthful patterns of gene expression and physiological activity ⁽³⁾. The therapy is therefore grounded in the emerging view that aging reflects a reversible loss of epigenetic information rather than permanent genetic damage.

The Epigenetic Basis of Aging- The Information Theory of Aging

Recent progress in aging biology has reshaped the understanding of why organisms grow old. Rather than viewing aging solely as the accumulation of irreversible molecular damage, emerging evidence suggests that cellular decline may largely reflect disruption of regulatory systems that control gene expression. This conceptual shift has gained clinical relevance with the FDA clearance of ER-100, the first gene therapy designed to test partial epigenetic reprogramming in humans ⁽⁴⁾. The therapy, developed by Life Biosciences, is grounded in a theoretical framework known as the Information Theory of Aging.

The Information Theory of Aging proposes that aging is driven primarily by the loss of epigenetic information rather than permanent damage to DNA ^{(5, 6, 7)}. Cells retain the full genetic blueprint throughout life, but progressive disorganization of epigenetic regulation impairs their ability to execute youthful gene-expression programs. In this view, the genome functions as stable hardware, while the epigenome acts as software that gradually becomes corrupted.

A central feature of the theory is the concept of epigenetic noise. Over time, DNA methylation patterns, histone modifications, and chromatin structure become increasingly disordered, leading to imprecise gene regulation. As this regulatory noise accumulates, cells lose functional stability, stress responses weaken, and tissue performance declines. Aging therefore reflects a failure of information maintenance rather than simple structural damage.

Crucially, because the underlying DNA remains largely intact, the theory predicts that aspects of aging should be reversible. Experimental support arises from cellular reprogramming studies demonstrating that aged cells can recover youthful phenotypes when epigenetic states are reset. These findings provide the intellectual basis for therapeutic strategies aimed at restoring epigenetic integrity.

The framework has been most prominently advanced by David Sinclair and colleagues, who articulated aging as an information-driven process and linked epigenetic dysregulation to functional decline ⁽⁸⁾. This perspective now underlies clinical efforts to evaluate whether controlled epigenetic reprogramming can restore cellular function in human disease.

Cellular Reprogramming and the Reversibility of Aging

The discovery that cellular age and identity are reversible emerged from induced pluripotent stem cell research^{( 9)}. Expression of four transcription factors, Oct-4, Sox-2, Klf-4, and c-Myc, was shown to reprogram adult cells into a pluripotent state. This process erases cell-type-specific epigenetic marks and resets biological age to an embryonic-like state, demonstrating that aging is actively maintained by epigenetic regulation.

However, full reprogramming is incompatible with therapeutic rejuvenation. Cells lose their specialized functions, tissues become destabilized, and the oncogenic factor c-Myc significantly increases cancer risk ⁽¹⁰⁾. In vivo experiments confirmed that uncontrolled expression of all four factors leads to tumor formation and lethality.

The critical breakthrough came with the realization that full reprogramming is unnecessary. By excluding c-Myc and tightly controlling the duration of factor expression, researchers developed partial reprogramming, a strategy that reverses age-associated epigenetic changes while preserving cellular identity ⁽¹¹⁾. The OSK combination emerged as particularly effective, providing rejuvenation without dedifferentiation or tumorigenesis.

The distinction between full and partial reprogramming lies in temporal control. Sustained expression over weeks drives pluripotency, whereas transient expression over days selectively removes aging-associated epigenetic marks. Cells remain fully differentiated but regain youthful molecular and functional characteristics.

Recent blog

Strategies for Developing Potency Assays for Epigenetic Drugs (Epidrugs)

Read the full post →

Mechanisms of OSK-Mediated Rejuvenation

Fig. 1: Gene Therapy for Anti-Aging: Partial Cellular Reprogramming with OSK Factors

OSK factors act as pioneer transcription factors capable of binding condensed chromatin and initiating large-scale epigenetic remodeling. During partial reprogramming, age-associated DNA methylation patterns are reset toward youthful states, including at sites used to measure epigenetic age. Chromatin accessibility is restored at regulatory regions that control cellular maintenance, while dysregulated histone modification patterns are corrected.

Heterochromatin, which is essential for genomic stability and becomes disrupted during aging, is also restored. These changes re-establish a youthful epigenetic landscape without erasing lineage-specific regulatory programs.

At the transcriptional level, rejuvenation reactivates genes involved in DNA repair, mitochondrial function, proteostasis, and stress resistance, while suppressing inflammatory and senescence-associated gene expression. Importantly, cell-type-specific gene networks regain robustness, improving specialized cellular functions rather than compromising them.

These molecular changes translate into measurable functional improvements. Rejuvenated cells show enhanced mitochondrial respiration, improved ATP production, reduced oxidative stress, and more effective protein quality-control systems. DNA repair capacity increases, resistance to cellular stress improves, and some senescent cells regain proliferative and functional competence.

Vision Restoration as Experimental Proof

The most compelling in vivo evidence for partial reprogramming comes from studies of age-related vision loss. Retinal ganglion cells, which degenerate in glaucoma and do not naturally regenerate, provide a stringent test of rejuvenation strategies. In animal models, delivery of OSK reversed glaucomatous damage, restored youthful epigenetic signatures, and recovered visual function ⁽¹²⁾.

Notably, partial reprogramming also promoted axonal regeneration in injured optic nerves, overcoming a long-standing barrier in neurobiology (Fig. 2). These effects occurred without tumor formation or loss of retinal cell identity, demonstrating that controlled rejuvenation can safely restore function in living organisms.

Fig. 2: Epigenetic Rejuvenation of Retinal Ganglion Cells by OSK-Mediated Gene Therapy.

Translating Rejuvenation into Gene Therapy

ER-100 translates partial reprogramming into a clinically viable gene-therapy platform. The therapy uses adeno-associated virus (AAV) vectors, which efficiently transduce non-dividing cells and persist without integrating into the genome. A dual-vector system provides precise temporal control: one vector carries the OSK genes, while a second vector enables doxycycline-dependent activation ⁽¹³⁾.

This design allows OSK expression to be externally controlled. Reprogramming occurs only while patients take doxycycline, enabling dose titration, defined treatment windows, and immediate cessation if adverse effects arise. Such control is essential for safely deploying a powerful biological intervention in humans.

Although vision loss is the initial clinical target, the implications extend far beyond ophthalmology. Aging underlies most chronic diseases, including neurodegeneration, cardiovascular disease, metabolic dysfunction, and immune decline. Partial epigenetic reprogramming offers a unified strategy to address these conditions by correcting the underlying regulatory causes of aging rather than treating downstream symptoms.

Conclusion

Gene-therapy-based epigenetic reprogramming represents a fundamental shift in the understanding of aging. By demonstrating that age-related decline arises from reversible loss of epigenetic information, this approach challenges the long-held view that aging is inevitable. The clinical testing of OSK-mediated rejuvenation marks the first direct attempt to translate this insight into human therapy.

If successful, partial reprogramming could inaugurate a new class of treatments that restore youthful cellular function rather than merely slowing degeneration. More broadly, it reframes aging as a modifiable biological state, opening the possibility of extending healthspan by addressing aging at its molecular root.

Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI) or Google Gemini.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.